

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/173473 A1

(51) International Patent Classification:

A23L 33/105 (2016.01) A61K 36/185 (2006.01)
A61K 31/353 (2006.01) A61P 43/00 (2006.01)
A61K 31/216 (2006.01) A61P 3/02 (2006.01)

(21) International Application Number:

PCT/US2024/015696

(22) International Filing Date:

14 February 2024 (14.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/484,981 14 February 2023 (14.02.2023) US

(71) Applicant: VDF FUTURECEUTICALS, INC. [US/US];

2692 N. State Rt. 1-17, Momence, Illinois 60954 (US).

(72) Inventors: NEMZER, Boris; 2692 N. State Rt. 1-17, Momence, Illinois 60954 (US). ZBIGNIEW, Pietrzkowski; 2692 N. State Rt. 1-17, Momence, Illinois 60954 (US). HUNTER, John M; 2692 N. State Rt. 1-17, Momence, Illinois 60954 (US).


(74) Agent: FESSENMAIER, Martin et al.; Umberg Zipser LLP, 1920 Main Street, Suite 750, Irvine, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: PLANT-BASED COMPOSITIONS AND METHODS FOR MODULATION OF INFLAMMATORY RESPONSE POST VIRAL INFECTION

FIG. 2



(57) Abstract: A polyphenol-rich composition is orally administered to alleviate a sign or symptom of a post-viral syndrome, and preferably post-COVID syndrome. Most typically, the composition comprises at least 50 wt% total catechins, at least 20 wt% total chlorogenic acids, and optionally up to 30 wt% total supplemental antioxidants. The composition may be formulated from a green coffee bean extract, a green tea extract, a turmeric extract, a tart cherry or extract thereof, a broccoli or extract thereof, and a kale or extract thereof. Notably, such compositions were effective in individuals post SARS-CoV2 infection to reduce proinflammatory cytokines and interleukins, increase NOHb, and to reduce reactive oxygen species due to mitochondrial dysfunction, iNOS activity, and NOX2 activity.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*